Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B
Open accessAbstract
Amphotericin B deoxycholate (AMB) has substantial toxicities. A novel encochleated amphotericin B deoxycholate (cAMB) formulation has oral bioavailability, efficacy in an animal model, and minimal toxicity due to targeted drug delivery into macrophages, where intracellular fungi reside. We conducted a phase I, ascending-dose trial of cAMB administered at 1.0 g, 1.5 g, or 2.0 g per day in 4 to 6 divided doses among HIV-positive survivors of cryptococcosis ( n = 9 per cohort).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CAmB provides a safe oral route for administering amphotericin B.
“CAmB offers safe oral administration of AmB”
From Investigational Agents for the Treatment of Resistant Yeasts and Molds (2021) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis
Boulware, D. R., Meya, D. B., Muzoora, C. K., Rolfes, M. A. R., Hullsiek, K. H., Musubire, A. K., Taseera, K., Nabeta, H. W., Schutz, C., Williams, D. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312884 · Cited by 497 · see citing works
Self-citationBekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.828-833.2002 · Cited by 320 · see citing works
Rhein, J., Hullsiek, K. H., Tugume, L., Nuwagira, E., Mpoza, E., Evans, E. E., Kiggundu, R., Pastick, K. A., Ssebambulidde, K., Akampurira, A., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30127-6 · Cited by 124 · see citing works
Self-citationEfficacy of Orally Delivered Cochleates Containing Amphotericin B in a Murine Model of Aspergillosis
Delmas, G., Park, S., Chen, Z. W., Tan, F., Kashiwazaki, R., Zarif, L., & Perlin, D. S. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2704-2707.2002 · Cited by 110 · see citing works
Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis
Lu, R., Hollingsworth, C., Qiu, J., Wang, A., Hughes, E., Xin, X., Konrath, K. M., Elsegeiny, W., Park, Y.-D., Atakulu, L., et al. (2019) · mBio · doi:10.1128/mbio.00724-19 · Cited by 67 · see citing works
Self-citationHalde, C., Newcomer, V. D., Wright, E. T., & Sternberg, T. H. (1957) · Journal of Investigative Dermatology · doi:10.1038/jid.1957.26 · Cited by 57 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 160 · see citing works
Frézard, F., Aguiar, M. G., Ferreira, L. A. M., Ramos, G. S., Santos, T. T. O., Borges, G. S. M., Vallejos, V. M. R., & de Morais, H. L. O. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010099 · Cited by 111 · see citing works
Advancements and challenges in antifungal therapeutic development
Puumala, E., Fallah, S., Robbins, N., & Cowen, L. E. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00142-23 · Cited by 118 · see citing works
“MAT2203, a novel encochleated amphotericin B formulation (CamB), was developed for oral administration by Matinas BioPharma (North Carolina, USA) (115).”
BackgroundMethodInfluentialAntifungal Drugs TDM: Trends and Update
Kably, B., Launay, M., Derobertmasure, A., Lefeuvre, S., Dannaoui, E., & Billaud, E. M. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000952 · Cited by 81 · see citing works
Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective
Lamoth, F., Lewis, R. E., & Kontoyiannis, D. P. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1070 · Cited by 79 · see citing works
Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial
Boulware, D. R., Atukunda, M., Kagimu, E., Musubire, A. K., Akampurira, A., Tugume, L., Ssebambulidde, K., Kasibante, J., Nsangi, L., Mugabi, T., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad440 · Cited by 75 · see citing works
Self-citationAmphotericin B in the Era of New Antifungals: Where Will It Stand?
Akinosoglou, K., Rigopoulos, E. A., Papageorgiou, D., Schinas, G., Polyzou, E., Dimopoulou, E., Gogos, C. A., & Dimοpoulos, G. (2024) · Journal of Fungi · doi:10.3390/jof10040278 · Cited by 56 · see citing works
“This suggests C-AmB could offer a safer and more convenient treatment option [151].”
BackgroundNanotechnology in the Diagnosis and Treatment of Antibiotic-Resistant Infections
Ιωάννου, Π., Baliou, S., & Samonis, G. (2024) · Antibiotics · doi:10.3390/antibiotics13020121 · Cited by 49 · see citing works
“One typical example is encochleated amphotericin B, a novel formulation of a well-known antifungal drug [138,139].”
BackgroundInfluentialMcCarty, T. P., & Pappas, P. G. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.732223 · Cited by 47 · see citing works
Chang, C. C., Hall, V. G., Cooper, C. M., Grigoriadis, G., Beardsley, J., Sorrell, T. C., & Heath, C. H. (2021) · Internal Medicine Journal · doi:10.1111/imj.15590 · Cited by 43 · see citing works
Diagnosis and management of cryptococcal meningitis in HIV-infected adults
McHale, T. C., Boulware, D. R., Kasibante, J., Ssebambulidde, K., Skipper, C. P., & Abassi, M. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00156-22 · Cited by 45 · see citing works
“This innovative formulation uses a lipid nanocrystal (LNC) to encase the amphotericin B to be orally bioavailable and delivered to monocytes and macrophages (111, 112).”
BackgroundMethodInfluentialSelf-citationUpdate on Pulmonary Cryptococcosis
Yamamura, D. L. R., & Xu, J. (2021) · Mycopathologia · doi:10.1007/s11046-021-00575-9 · Cited by 39 · see citing works
Antifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35 · see citing works
How urgent is the need for new antifungals?
Stewart, A. G., & Paterson, D. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1935868 · Cited by 36 · see citing works
Natural Polyketides Act as Promising Antifungal Agents
Wang, L., Lu, H., & Jiang, Y. (2023) · Biomolecules · doi:10.3390/biom13111572 · Cited by 36 · see citing works
“CAmB demonstrates in vitro activity against C. neoformans , Candida species, and A. fumigatus [46].”
BackgroundInvestigational Agents for the Treatment of Resistant Yeasts and Molds
Seiler, G. T., & Ostrosky-Zeichner, L. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00419-5 · Cited by 32 · see citing works
Formulation Strategies to Overcome Amphotericin B Induced Toxicity
Dash, S. K., Benival, D. M., & Jindal, A. B. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00485 · Cited by 33 · see citing works
Review of Novel Oral Amphotericin B Formulations for the Treatment of Parasitic Infections
Wasan, E. K., Mandava, T. T., Crespo-Moran, P., Nagy, A., & Wasan, K. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112316 · Cited by 33 · see citing works
The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives
de Souza, C. M., Bezerra, B. T., Mellon, D. A., & de Oliveira, H. C. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100341 · Cited by 35 · see citing works
Bioresponsive engineered nanoparticles for immunomodulation
Hegde, M., Mishra, A., Banerjee, R., Bintee, B., Alqahtani, M. S., Abbas, M., Shanmugam, M. K., Drum, C. L., Sethi, G., Liu, L., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04305-6 · Cited by 33 · see citing works
“These studies observed no indications of renal, hepatic, or hematologic toxicity during its course (NCT02971007, NCT02629419, NCT04031833) [362, 396].”
InfluentialBrienze, V. M. S., André, J. C., Liso, E., & Louis, I. V.-S. (2021) · Life · doi:10.3390/life11020095 · Cited by 28 · see citing works
Recent advances and future perspectives in the pharmacological treatment ofCandida aurisinfections
Giacobbe, D. R., Magnasco, L., Sepulcri, C., Mikulska, M., Koehler, P. A., Cornely, O. A., & Bassetti, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1949285 · Cited by 27 · see citing works
Fairuz, S., Nair, R. S., & Billa, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091823 · Cited by 26 · see citing works
Efficacy of Cochleated Amphotericin B in Mouse and Human Mucocutaneous Candidiasis
Desai, J. V., Urban, A. K., Swaim, D., Colton, B., Kibathi, L. W., Ferré, E. M. N., Stratton, P., Merideth, M. A., Hunsberger, S., Matkovits, T., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00308-22 · Cited by 24 · see citing works
Self-citationEmerging Diagnostics and Therapeutics for Invasive Fungal Infections
Friedman, D. Z. P., & Schwartz, I. S. (2023) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2023.05.001 · Cited by 23 · see citing works
Zhong, X., Yang, J., Liu, H., Yang, Z., & Luo, P. (2023) · Drug Delivery · doi:10.1080/10717544.2022.2161671 · Cited by 23 · see citing works
“All these participants upon oral encochleated AmB had a positive clinical response, with no evidence of drug side effects apart from slight gastrointestinal discomfort (Skipper et al., 2020; U.S. National Library of Medicine, 2020).”
BackgroundInfluentialUpdates on Histoplasmosis in Solid Organ Transplantation
Saullo, J. L., & Miller, R. A. (2022) · Current Fungal Infection Reports · doi:10.1007/s12281-022-00441-1 · Cited by 21 · see citing works
An overview of current and emerging antifungal pharmacotherapy for invasive fungal infections
Mueller, S. W., Kedzior, S. K., Miller, M. A., Reynolds, P., Kiser, T. H., Kršák, M., & Molina, K. C. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1892075 · Cited by 19 · see citing works
“showed no renal toxicity in 9 patients [94].”
BackgroundJacobson, E., Morton, J. M., Woerde, D. J., Thompson, M., Spillane, A. M., Tebb, A. J., della Valle, Z., Birnie, G., & Malík, R. (2022) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.22.08.0342 · Cited by 17 · see citing works
Oral Lipid Nanocrystal Amphotericin B (MAT2203) for the Treatment of Invasive Fungal Infections
Dalton, L. M., Kauffman, C. A., & Miceli, M. H. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae346 · Cited by 16 · see citing works
“MAT2203 was associated with lower toxicity and demonstrated survival benefit similar to that of intravenous AmB in patients with HIV-associated cryptococcal meningitis [14, 15].”
BackgroundResultNovel Approaches in the Management of Mucormycosis
Lamoth, F. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00463-3 · Cited by 16 · see citing works
Maciel-Magalhães, M., Medeiros, R. J., Guedes, N. C. D. C., de Brito, T. M., de Souza, G. F., Canabarro, B. R., Ferraris, F. K., Amendoeira, F. C., Rocha, H. V. A., Patricio, B. F. D. C., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010116 · Cited by 15 · see citing works
“Recently, studies utilizing nanotechnology to address this challenge have increased significantly [4–7].”
Hsu, A. J., Hanisch, B. R., Fisher, B. T., & Huppler, A. R. (2024) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piad115 · Cited by 15 · see citing works
Current Antifungals and the Developing Pipeline
Johnson, M. D., & Moore, W. J. (2025) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.01.001 · Cited by 11 · see citing works
Gu, Y., Gebremariam, T., Alkhazraji, S., Youssef, E., El-Gamal, S., Matkovits, T., Cobb, J., Mannino, R. J., & Ibrahim, A. S. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01540-23 · Cited by 10 · see citing works
“This dose is below the dose level of 1–2 g/day tested in the Phase 1 EnACT trial showing that the drug was well tolerated when given in 4–6 divided daily doses (19).”
BackgroundSelf-citationAn update on newer antifungals
Akinosoglou, K., Papageorgiou, D., Gogos, C. A., & Dimοpoulos, G. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2461566 · Cited by 10 · see citing works
“According to phase I EnACT trial C-AmB was generally safe, well-tolerated at doses up to 2.0 g/day divided in 4 to 6 daily doses, and had a more favorable toxicity profile compared to intravenous (IV) AmB, with 95% of participants completing treatment without grade 3 or worse adverse events [66].”
InfluentialSharifi, N., Alitaneh, Z., Asadi, S., Vahidinia, Z., Zarch, S. M. A., Esmaeili, A., Bagheri‐Mohammadi, S., Najafi, S., & Mazhari, Y. (2023) · Biotechnology Journal · doi:10.1002/biot.202300462 · Cited by 9 · see citing works
Combination Therapy for HIV-Associated Cryptococcal Meningitis—A Success Story
Hurt, W. J., Harrison, T. S., Molloy, S. F., & Bicanic, T. A. (2021) · Journal of Fungi · doi:10.3390/jof7121098 · Cited by 8 · see citing works
“The development of surrogate markers of treatment efficacy were key to the success of developing novel combinations regimens as well as optimising dosing, markers that are now being deployed in the evaluation of novel agents in the antifungal armamentarium against Cryptococcus, including APX2039 and oral (encochleated…”
BackgroundEspinel‐Ingroff, A., & Cantón, E. (2023) · Journal of Fungi · doi:10.3390/jof9050542 · Cited by 7 · see citing works
“The same applies to the new oral encochleate amphotericin B (reduced toxicity) that had a similar efficacy to parenteral amphotericin B plus flucytosine in a cryptococcal meningoencephalitis mouse model [16].”
BackgroundCandida auris in intensive care unit: A growing clinical concern
Bassetti, M., Magnasco, L., Lamarina, A., Paola, L. D., Vena, A., Giacobbe, D. R., & Bartalucci, C. (2025) · Journal of Translational Critical Care Medicine · doi:10.1097/jtccm-d-25-00003 · Cited by 6 · see citing works
New and emerging drugs for the treatment of invasive fungal infections
Maves, R. C., & Fowler, M. N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2568547 · Cited by 5 · see citing works
“Oral treatment of cryptococcal meningitis with CAmB is undergoing clinical trials at present, as noted above, with promising preliminary data suggesting that it may supplant IV LAmB in the coming years [73,79].”
InfluentialJi, C., Qiu, Z., Yang, Z., & Luo, P. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105347 · Cited by 5 · see citing works
New antifungals for the treatment of invasive mould disease
Vuong, N. N., McClung, D. R., Aitken, S. L., & Rausch, C. R. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.03.035 · Cited by 3 · see citing works
Ahimbisibwe, C., Kwizera, R., Ndyetukira, J. F., Namuju, O. C., Sadiq, A., Atukunda, M., Skipper, C. P., Boulware, D. R., & Meya, D. B. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11319-1 · Cited by 3 · see citing works
“Oral cAMB was well tolerated clinically when given in 4 to 6 divided daily doses without the toxicities commonly seen with intravenous amphotericin B [12].”
InfluentialSelf-citationNovel agents in the treatment of invasive fungal infections in solid organ transplant recipients
Cabrera, N. L., George, I. A., Rauseo, A. M., Mazi, P. B., & Spec, A. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000995 · Cited by 3 · see citing works
New Antifungal Drugs: Discovery and Therapeutic Potential
Vicente, F., Reyes, F., & Genilloud, O. (2024) · Springer eBooks · doi:10.1007/978-981-99-5696-8_12 · Cited by 3 · see citing works
Milsap, D., Okuno, M., Kigozi, E., Mugabi, T., Ssekindi, F., Bajer, A., Gakuru, J., & Bahr, N. C. (2025) · Microorganisms · doi:10.3390/microorganisms13040847 · Cited by 4 · see citing works
“A phase I trial reported good tolerability and safety of LNC amphotericin [31].”
Maciel-Magalhães, M., Ybarra, D. E., Vega, D. M., Sosa, A. M., Canabarro, B. R., da Silva, F. F. F., Rocha, H. V. A., Martinez, C. S., Prieto, M. J., Delgado, I. F., et al. (2025) · ACS Omega · doi:10.1021/acsomega.5c05091 · Cited by 2 · see citing works
The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis
Zubovskaia, A., & Vázquez, J. A. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s547511 · Cited by 2 · see citing works
Nanoformulations of amphotericin B to resolve challenges in antifungal therapy
Patel, M., Jain, V. K., Popli, H., & Jain, K. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2407281 · Cited by 1 · see citing works
Management of Candida Infections of the Urinary System
Stewart, A. G., & Hammond, S. P. (2026) · Current Fungal Infection Reports · doi:10.1007/s12281-026-00527-0 · Cited by 1 · see citing works
Neue Antimykotika: Hoffnungsträger in der Therapie invasiver Mykosen?
Aldejohann, A. M., Kurzai, O., von Lilienfeld‐Toal, M., & Rüthrich, M. M. (2022) · Krankenhaushygiene up2date · doi:10.1055/a-1400-8371 · Cited by 1 · see citing works
Sadiq, A., Kwizera, R., Kiiza, T. K., Ayebare, P., Ahimbisibwe, C., Ndyetukira, J. F., Boulware, D. R., & Meya, D. B. (2025) · AIDS Research and Therapy · doi:10.1186/s12981-025-00705-z · Cited by 1 · see citing works
“ENACT The Encochleated Oral Amphotericin for Cryp-tococcal Meningitis (ENACT) was a phase I and II trials evaluating the safety and tolerability of a novel oral formulation of Amphotericin B [16, 26].”
Self-citationAspergillus-Human Interactions: From the Environment to Clinical Significance
Thammahong, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98509
Teens and Part-Time Jobs: At What Price?.
Kuersten, J. (2001) · Our children
Antifúngicos: lo que tenemos, lo que tendremos, lo que queremos.
Martínez-Méndez, D., Bravo-Acosta, M., & Semprún-Hernández, N. (2023) · Investigación Clínica · doi:10.54817/ic.v64n4a11
Novel Therapeutic Approaches to Control Fungal Biofilms
Guisso, L. P., Ribeiro, N. P., Carmona, W. R., Roseno, A. C. B., Pessan, J. P., & Monteiro, D. R. (2025) · Springer series on biofilms · doi:10.1007/978-3-031-93315-8_11
Innovative liposomal amphotericin B formulation for oral treatment of visceral leishmaniasis
de Morais, H. L. O., Ramos, G. S., Vallejos, V. M. R., Santos, T. T. O., Silva, P. H. R., Facci, J., Fujiwara, R. T., Teobaldo, G. B. M., Oliveira, C. L. P., Fernandes, C., et al. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127414
The role of nanomedicine in infectious diseases of the central nervous system: a narrative review
Somerville, S., & Bach, H. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2749655
- Authors
- Skipper, C. P., Atukunda, M., Stadelman, A., Engen, N. W., Bangdiwala, A. S., Hullsiek, K. H., Abassi, M., Rhein, J., Nicol, M. R., Laker, E., Williams, D. A., Mannino, R., Matkovits, T., Meya, D. B., & Boulware, D. R.
- Affiliations
- University of Minnesota (US)
- Infectious Diseases Institute (UG)
- Jupiter (United States) (US)
- Corresponding author
- Skipper, Caleb P.
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2020-09-21
- Volume
- 64
- Issue
- 10
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC7508607
- OpenAlex
- W3045760297
- Cited by
- 60
- References
- 6
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 11 · 2023: 10 · 2022: 9 · 2021: 12
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Institute of Allergy and Infectious Diseases (T32AI055433)
- HHS | NIH | Fogarty International Center (D43TW009345, K01TW010268)
- HHS | NIH | National Institute of Neurological Disorders and Stroke (R01NS110519)
- Topics
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Epidemiology › Pneumocystis jirovecii pneumonia detection and treatment
- Keywords
- amphotericin B deoxycholate, oral dosage forms, drug safety and tolerability, cryptococcosis, HIV, cryptococcal meningitis, macrophage-targeted drug delivery, antifungal therapy
- MeSH terms
- Amphotericin B, Animals, Antifungal Agents, Cryptococcosis, Fungi
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
